Show simple item record

dc.contributor.advisorAkabani, Gamalen_US
dc.contributor.advisorPoston, John W.en_US
dc.creatorZhou, Jingjieen_US
dc.date.accessioned2011-08-08T22:48:40Zen_US
dc.date.accessioned2011-08-09T01:32:48Z
dc.date.available2011-08-08T22:48:40Zen_US
dc.date.available2011-08-09T01:32:48Z
dc.date.created2011-05en_US
dc.date.issued2011-08-08en_US
dc.date.submittedMay 2011en_US
dc.identifier.urihttp://hdl.handle.net/1969.1/ETD-TAMU-2011-05-9391en_US
dc.description.abstractA novel Y-90 liquid brachytherapy strategy is currently being studied for the treatment of osteosarcoma using a preclinical translational model in dogs to assess its potential efficacy and toxicity. In this study, dosimetry calculations are performed for Y-90 liquid brachytherapy in a dog with osteosarcoma using the Geant4 Monte Carlo code. A total of 611.83 MBq Y-90 radiopharmaceutical is administered via direct injections, and the in vivo distribution of Y-90 is assessed using a time-of-flight (TOF) PET/CT scanner. A patient-specific geometry is built using anatomical data obtained from CT images. The material properties of tumor and surrounding tissues are calculated based on a CT number - electron density calibration. The Y-90 distribution is sampled in Geant4 from PET images using a collapsing 3-D rejection technique to determine the decay sites. Dose distributions in the tumor bed and surrounding tissues are calculated demonstrating significant heterogeneity with multiple hot spots at the injection sites. Dose volume histograms show about 33.9 percent of bone and tumor and 70.2 percent of bone marrow and trabecular bone receive a total dose over 200 Gy; about 3.2 percent of bone and tumor and 31.0 percent of bone marrow and trabecular bone receive a total dose of over 1000 Gy. Y-90 liquid brachytherapy has the potential to be used as an adjuvant therapy or for palliation purposes. Future work includes evaluation of pharmacokinetics of the Y-90 radiopharmaceutical, calibration of PET/CT scanners for the direct quantitative assessment of Y-90 activity concentration, and assessment of efficacy of the Y-90 liquid brachytherapy strategy.en_US
dc.format.mimetypeapplication/pdfen_US
dc.language.isoen_USen_US
dc.subjectliquid brachytherapyen_US
dc.subjectMonte Carloen_US
dc.subjectdosimetryen_US
dc.subjectPET/CTen_US
dc.subjectosteosarcomaen_US
dc.subjectpreclinicalen_US
dc.subjectGeant4en_US
dc.titleDosimetry of Y-90 Liquid Brachytherapy in a Dog with Osteosarcoma Using PET/CTen_US
dc.typeThesisen
thesis.degree.departmentNuclear Engineeringen_US
thesis.degree.disciplineHealth Physicsen_US
thesis.degree.grantorTexas A&M Universityen_US
thesis.degree.nameMaster of Scienceen_US
thesis.degree.levelMastersen_US
dc.contributor.committeeMemberLenox, Mark W.en_US
dc.type.genrethesisen_US
dc.type.materialtexten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record